Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Fellow in Hematology-Oncology, Medicine, Duke University 2008
  • Fellow in Hematology-Oncology, Medicine, University of Pennsylvania 2005 - 2007
  • Resident, Medicine, University of North Carolina at Chapel Hill 2001 - 2004
  • M.D., Drexel University 2001
• 

  Duke Appointment History

  • Medical Instructor in the Department of Medicine, Medicine, Hematology, Medicine 2008 - 2012
  • Instructor, Temporary in the Department of Medicine, Medicine, Hematology, Medicine 2008
• Research
• 

  Selected Grants

  • Phase IV open label study of Emicizumab Prophylaxis in Hemophila A patients undergoing minor surgery awarded by Genentech, Inc. 2018 - 2021
  • Follow-up Study for Patients who Completed Study ALX0681-C301 (Post-HERCULES) awarded by Ablynx 2016 - 2021
  • Prospective Randomized open blinded end-point (PROBE) study awarded by Baim Institute for Clinical Research 2018 - 2021
  • Transfusion Medicine and Hematology awarded by National Institutes of Health 1975 - 2021
  • POST-MARKETING non-interventional safety evaluation of obizur in the treatment of bleeding episodes for patients with acquired hemophilia A awarded by Baxalta, Inc. 2016 - 2020
  • An open-label, multicenter, Post-Marketing Requirement study to investigate the safety and tolerability of octaplas in the management of pediatric patients who require therapeutic plasma exchange awarded by Octapharma AG 2017 - 2019
  • OMS721 in TMA awarded by Omeros 2014 - 2019
  • ART Study (Rituximab as adjunct therapy with plasma exchange in TTP patients) awarded by Washington University School of Medicine 2015 - 2019
  • Edoxaban in VTE Associated with Cancer Hokusai VTE Cancer Study DU176b-D-U311 awarded by Daiichi Sankyo Inc 2015 - 2019
  • Microfluidic quartz resonator based blood plasma coagulation monitors awarded by Qatch Technologies LLC 2017 - 2018
  • A Phase III Trial with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura awarded by Ablynx 2016 - 2017
  • RE-VERSE-AD (A Study of the RE-VERSal Effects of Idarucizumab on Active Dabigatran) Trial awarded by Boehringer Ingelheim Pharmaceuticals, Inc. 2015 - 2017
  • Public Health Surveillance of Bleeding awarded by Centers for Disease Control and Prevention 2011 - 2016
  • GSK AML awarded by GlaxoSmithKline 2013 - 2016
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Scully, Marie, Spero R. Cataland, Flora Peyvandi, Paul Coppo, Paul Knöbl, Johanna A. Kremer Hovinga, Ara Metjian, et al. “Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura..” The New England Journal of Medicine 380, no. 4 (January 9, 2019): 335–46. https://doi.org/10.1056/nejmoa1806311.
       Full Text
    • Onwuemene, Oluwatoyosi A., Steven C. Grambow, Chetan B. Patel, Robert J. Mentz, Carmelo A. Milano, Joseph G. Rogers, Ara D. Metjian, Gowthami M. Arepally, and Thomas L. Ortel. “Indications for and outcomes of therapeutic plasma exchange after cardiac transplantation: A single center retrospective study..” Journal of Clinical Apheresis 33, no. 4 (August 2018): 469–79. https://doi.org/10.1002/jca.21622.
       Full Text
    • Diep, Robert, and Ara Metjian. “A rare CALR variant mutation and a review of CALR in essential thrombocythemia..” Journal of Thrombosis and Thrombolysis 45, no. 3 (April 2018): 457–62. https://doi.org/10.1007/s11239-018-1619-0.
       Full Text
    • Tanhehco, Yvette C., Gowthami Arepally, and Ara Metjian. “Novel therapeutic approaches for thrombotic thrombocytopenic purpura..” Current Opinion in Hematology 24, no. 6 (November 2017): 521–28. https://doi.org/10.1097/moh.0000000000000375.
       Full Text
    • Abbes, Sarah, Ara Metjian, Alice Gray, Tereza Martinu, Laurie Snyder, Dong-Feng Chen, Matthew Ellis, Gowthami M. Arepally, and Oluwatoyosi Onwuemene. “Human Leukocyte Antigen Sensitization in Solid Organ Transplantation: A Primer on Terminology, Testing, and Clinical Significance for the Apheresis Practitioner..” Therapeutic Apheresis and Dialysis : Official Peer Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 21, no. 5 (October 2017): 441–50. https://doi.org/10.1111/1744-9987.12570.
       Full Text
    • Metjian, Ara, Yvette C. Tanhehco, Nicole Aqui, Vijay G. Bhoj, Lita Jamensky, Marisa B. Marques, Oluwatoyosi Onwuemene, Huy P. Pham, and Gowthami M. Arepally. “The thrombotic microangiopathy Registry of North America: A United States multi-institutional TMA network..” Journal of Clinical Apheresis 31, no. 5 (October 2016): 448–53. https://doi.org/10.1002/jca.21437.
       Full Text
    • Metjian, Ara D. “rVWF: treatment finally reaches the modern age..” Blood 126, no. 17 (October 2015): 1975–76. https://doi.org/10.1182/blood-2015-08-664052.
       Full Text
    • Nipp, Ryan, Aaron Mitchell, Allyson Pishko, and Ara Metjian. “Waldenström macroglobulinemia in hepatitis C: case report and review of the current literature..” Case Reports in Oncological Medicine 2014 (January 2014). https://doi.org/10.1155/2014/165670.
       Full Text
    • Patil, Avinash S., Sarah K. Dotters-Katz, Ara D. Metjian, Andra H. James, and Geeta K. Swamy. “Use of a thrombopoietin mimetic for chronic immune thrombocytopenic purpura in pregnancy..” Obstet Gynecol 122, no. 2 Pt 2 (August 2013): 483–85. https://doi.org/10.1097/AOG.0b013e31828d5b56.
       Full Text  Link to Item
    • Sood, S. L., A. Cuker, C. Wang, A. D. Metjian, E. Y. Chiang, J. M. Soucie, B. A. Konkle, and B. A. HTCN Study Investigators. “Similarity in joint function limitation in Type 3 von Willebrand's disease and moderate haemophilia A..” Haemophilia : The Official Journal of the World Federation of Hemophilia 19, no. 4 (July 2013): 595–601. https://doi.org/10.1111/hae.12119.
       Full Text
    • Sood, S. L., A. Cuker, C. Wang, A. D. Metjian, E. Y. Chiang, J. M. Soucie, and B. A. Konkle. “Similarity in joint function limitation in Type 3 von Willebrand's disease and moderate haemophilia A.” Haemophilia 19, no. 4 (2013): 595–601. https://doi.org/10.1111/hae.12119.
       Full Text
    • Silbermins, D., and A. D. Metjian. “Hematology,” December 1, 2012, 404–48. https://doi.org/10.1016/B978-0-323-06398-2.00015-1.
       Full Text
    • Lee, G., W. Duan-Porter, and Ara D. Metjian. “Acquired, non-amyloid related factor X deficiency: review of the literature..” Haemophilia : The Official Journal of the World Federation of Hemophilia 18, no. 5 (September 2012): 655–63. https://doi.org/10.1111/j.1365-2516.2012.02773.x.
       Full Text
    • Whitlatch, Nicole L., David F. Kong, Ara D. Metjian, Gowthami M. Arepally, and Thomas L. Ortel. “Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia..” Blood 116, no. 10 (September 2010): 1761–66. https://doi.org/10.1182/blood-2010-01-262659.
       Full Text
    • Metjian, A. D., C. Wang, S. L. Sood, A. Cuker, S. M. Peterson, J. M. Soucie, B. A. Konkle, and B. A. HTCN Study Investigators. “Bleeding symptoms and laboratory correlation in patients with severe von Willebrand disease..” Haemophilia : The Official Journal of the World Federation of Hemophilia 15, no. 4 (July 2009): 918–25. https://doi.org/10.1111/j.1365-2516.2009.02025.x.
       Full Text
    • Metjian, Ara, and Charles S. Abrams. “New advances in the treatment of adult chronic immune thrombocytopenic purpura: role of thrombopoietin receptor-stimulating agents..” Biologics : Targets & Therapy 3 (January 2009): 499–513.
    • Metjian, Ara, and Wendy Lim. “ASH evidence-based guidelines: should asymptomatic patients with antiphospholipid antibodies receive primary prophylaxis to prevent thrombosis?.” Hematology. American Society of Hematology. Education Program, January 2009, 247–49. https://doi.org/10.1182/asheducation-2009.1.247.
       Full Text
    • Metjian, Ara, and Charles S. Abrams. “New insights and therapeutics for immune-mediated thrombocytopenia..” Expert Review of Cardiovascular Therapy 6, no. 1 (January 2008): 71–84. https://doi.org/10.1586/14779072.6.1.71.
       Full Text
    • Metjian, A., R. L. Roll, A. D. Ma, and C. S. Abrams. “Agonists cause nuclear translocation of phosphatidylinositol 3-kinase gamma. A Gbetagamma-dependent pathway that requires the p110gamma amino terminus..” J Biol Chem 274, no. 39 (September 24, 1999): 27943–47. https://doi.org/10.1074/jbc.274.39.27943.
       Full Text  Link to Item
    • Ma, A. D., A. Metjian, S. Bagrodia, S. Taylor, and C. S. Abrams. “Cytoskeletal reorganization by G protein-coupled receptors is dependent on phosphoinositide 3-kinase gamma, a Rac guanosine exchange factor, and Rac..” Molecular and Cellular Biology 18, no. 8 (August 1998): 4744–51. https://doi.org/10.1128/mcb.18.8.4744.
       Full Text

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.